These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24077600)

  • 1. Virtual drug design: Skp1-Skp2 inhibition targets cancer stem cells.
    Pascal LE; Wang Z
    Asian J Androl; 2013 Nov; 15(6):717-8. PubMed ID: 24077600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression.
    Chan CH; Morrow JK; Li CF; Gao Y; Jin G; Moten A; Stagg LJ; Ladbury JE; Cai Z; Xu D; Logothetis CJ; Hung MC; Zhang S; Lin HK
    Cell; 2013 Aug; 154(3):556-68. PubMed ID: 23911321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skp2: a dream target in the coming age of cancer therapy.
    Chan CH; Morrow JK; Zhang S; Lin HK
    Cell Cycle; 2014; 13(5):679-80. PubMed ID: 24526126
    [No Abstract]   [Full Text] [Related]  

  • 4. A patent review of SCF E3 ligases inhibitors for cancer：Structural design, pharmacological activities and structure-activity relationship.
    Zeng J; Chen Z; He Y; Jiang Z; Zhang Y; Dong Q; Chen L; Deng S; He Z; Li L; Li J; Shi J
    Eur J Med Chem; 2024 Nov; 278():116821. PubMed ID: 39232359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
    Masumoto K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
    Chen Q; Xie W; Kuhn DJ; Voorhees PM; Lopez-Girona A; Mendy D; Corral LG; Krenitsky VP; Xu W; Moutouh-de Parseval L; Webb DR; Mercurio F; Nakayama KI; Nakayama K; Orlowski RZ
    Blood; 2008 May; 111(9):4690-9. PubMed ID: 18305219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
    Kitagawa K; Kitagawa M
    Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of SCF-Skp2/Cks1 E3 ligase block estrogen-induced growth stimulation and degradation of nuclear p27kip1: therapeutic potential for endometrial cancer.
    Pavlides SC; Huang KT; Reid DA; Wu L; Blank SV; Mittal K; Guo L; Rothenberg E; Rueda B; Cardozo T; Gold LI
    Endocrinology; 2013 Nov; 154(11):4030-45. PubMed ID: 24035998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer.
    Bochis OV; Irimie A; Pichler M; Berindan-Neagoe I
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):225-34. PubMed ID: 26114183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics and chemical library screens reveal a novel SCF
    Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
    Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular dynamics simulations elucidate the mode of protein recognition by Skp1 and the F-box domain in the SCF complex.
    Chandra Dantu S; Nathubhai Kachariya N; Kumar A
    Proteins; 2016 Jan; 84(1):159-71. PubMed ID: 26573739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of human CUL-1 and ubiquitin-conjugating enzyme CDC34 with the F-box protein p45(SKP2): evidence for evolutionary conservation in the subunit composition of the CDC34-SCF pathway.
    Lisztwan J; Marti A; Sutterlüty H; Gstaiger M; Wirbelauer C; Krek W
    EMBO J; 1998 Jan; 17(2):368-83. PubMed ID: 9430629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis.
    Wang G; Chan CH; Gao Y; Lin HK
    Chin J Cancer; 2012 Apr; 31(4):169-77. PubMed ID: 22200179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCFSkp2-Cks1.
    Ungermannova D; Lee J; Zhang G; Dallmann HG; McHenry CS; Liu X
    J Biomol Screen; 2013 Sep; 18(8):910-20. PubMed ID: 23589337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brusatol has therapeutic efficacy in non-small cell lung cancer by targeting Skp1 to inhibit cancer growth and metastasis.
    Xing S; Nong F; Wang Y; Huang D; Qin J; Chen YF; He DH; Wu PE; Huang H; Zhan R; Xu H; Liu YQ
    Pharmacol Res; 2022 Feb; 176():106059. PubMed ID: 34998973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skp1: Implications in cancer and SCF-oriented anti-cancer drug discovery.
    Hussain M; Lu Y; Liu YQ; Su K; Zhang J; Liu J; Zhou GB
    Pharmacol Res; 2016 Sep; 111():34-42. PubMed ID: 27238229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of neddylation and deneddylation of cullin1 in SCFSkp2 ubiquitin ligase by F-box protein and substrate.
    Bornstein G; Ganoth D; Hershko A
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11515-20. PubMed ID: 16861300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticancer drugs: Breaking a cancerous interaction.
    Harrison C
    Nat Rev Drug Discov; 2013 Oct; 12(10):740. PubMed ID: 24052048
    [No Abstract]   [Full Text] [Related]  

  • 19. [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].
    Yu Q; Xiong X; Sun Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(1):1-19. PubMed ID: 32621419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic identification of the oncoprotein STAT3 as a target of a novel Skp1 inhibitor.
    Cheng X; Liu YQ; Wang GZ; Yang LN; Lu YZ; Li XC; Zhou B; Qu LW; Wang XL; Cheng YX; Liu J; Tao SC; Zhou GB
    Oncotarget; 2017 Jan; 8(2):2681-2693. PubMed ID: 27835873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.